Fulcrum Therapeutics, Inc. (FULC)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
8.29 USD
+0.30
(3.755%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.29 Short-term: ★★☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:21 a.m. EDT
A classic 'value trap' with speculative hedging preventing a crash but failing to capitalize on momentum. The 41.1% spike in short interest coupled with a negative 45-day forecast (-1.52%) and negative free cash flow (-$34M) indicates the market is skeptical of the short-term bullish narrative, despite Phase 1b trial success that may not have translated to enough operational cash flow to offset dilution. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.242635 |
| AutoETS | 0.254995 |
| AutoARIMA | 0.254995 |
| AutoTheta | 0.261437 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 19.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.162 |
| Excess Kurtosis | -1.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.846 |
| Market Cap | 552,115,712 |
| Forward P/E | -5.17 |
| Beta | 3.27 |
| Website | https://www.fulcrumtx.com |
As of April 19, 2026, 12:21 a.m. EDT: Options flow indicates significant put buying for downside protection, particularly at the June 18 expiration, where Volume at $6.00 is 504 with OI at 414. Conversely, Call open interest is heavily concentrated near current price levels (June 18: 4.0k OI at $8.00), suggesting speculation on range-bound recovery to the $8.00 support rather than a major expansion. The imbalance in put OI volume vs call OI implies hedging sentiment or 'pin risk' positioning around the current price, which may result in a 'pin' effect preventing lower downside but also capping upside. Long-dated (Jan 27) calls show OI at very high strikes ($27.00), indicating deep-out-of-the-money speculative bets on a massive price surge.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3959537 |
| Address1 | 26 Landsdowne Street |
| All Time High | 33.098 |
| All Time Low | 2.25 |
| Ask | 8.32 |
| Ask Size | 3 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 822,440 |
| Average Daily Volume3 Month | 1,035,404 |
| Average Volume | 1,035,404 |
| Average Volume10Days | 822,440 |
| Beta | 3.268 |
| Bid | 8.26 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 5.242 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.29 |
| Current Ratio | 27.397 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.365 |
| Day Low | 7.88 |
| Debt To Equity | 1.846 |
| Display Name | Fulcrum Therapeutics |
| Earnings Call Timestamp End | 1,771,938,000 |
| Earnings Call Timestamp Start | 1,771,938,000 |
| Earnings Timestamp | 1,771,939,800 |
| Earnings Timestamp End | 1,777,552,200 |
| Earnings Timestamp Start | 1,777,552,200 |
| Ebitda | -83,379,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.474 |
| Enterprise Value | 206,252,736 |
| Eps Current Year | -1.29989 |
| Eps Forward | -1.60322 |
| Eps Trailing Twelve Months | -1.18 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.4056 |
| Fifty Day Average Change | -0.11559963 |
| Fifty Day Average Change Percent | -0.013752693 |
| Fifty Two Week Change Percent | 139.59537 |
| Fifty Two Week High | 15.74 |
| Fifty Two Week High Change | -7.45 |
| Fifty Two Week High Change Percent | -0.47331637 |
| Fifty Two Week Low | 3.17 |
| Fifty Two Week Low Change | 5.12 |
| Fifty Two Week Low Change Percent | 1.6151419 |
| Fifty Two Week Range | 3.17 - 15.74 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,563,456,600,000 |
| Float Shares | 43,647,779 |
| Forward Eps | -1.60322 |
| Forward P E | -5.1708436 |
| Free Cashflow | -33,922,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -56,103,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03856 |
| Held Percent Institutions | 1.01584 |
| Implied Shares Outstanding | 66,600,209 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Fulcrum Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 552,115,712 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_376267397 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -74,880,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 552,781,734 |
| Number Of Analyst Opinions | 10 |
| Open | 8.14 |
| Operating Cashflow | -60,065,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 651 8851 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 8.29 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 7.99 |
| Price Eps Current Year | -6.3774624 |
| Price Hint | 2 |
| Price To Book | 1.5814574 |
| Profit Margins | 0.0 |
| Quick Ratio | 27.083 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.3 |
| Regular Market Change Percent | 3.7547 |
| Regular Market Day High | 8.365 |
| Regular Market Day Low | 7.88 |
| Regular Market Day Range | 7.88 - 8.365 |
| Regular Market Open | 8.14 |
| Regular Market Previous Close | 7.99 |
| Regular Market Price | 8.29 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,028,761 |
| Return On Assets | -0.169 |
| Return On Equity | -0.25296 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 66,600,209 |
| Shares Percent Shares Out | 0.104499996 |
| Shares Short | 6,962,035 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,210,945 |
| Short Name | Fulcrum Therapeutics, Inc. |
| Short Percent Of Float | 0.1393 |
| Short Ratio | 5.04 |
| Source Interval | 15 |
| State | MA |
| Symbol | FULC |
| Target High Price | 25.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 19.0 |
| Target Median Price | 21.5 |
| Total Cash | 352,305,984 |
| Total Cash Per Share | 5.29 |
| Total Debt | 6,443,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.18 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.84025 |
| Two Hundred Day Average Change | -0.55025005 |
| Two Hundred Day Average Change Percent | -0.062243722 |
| Type Disp | Equity |
| Volume | 1,028,761 |
| Website | https://www.fulcrumtx.com |
| Zip | 2,139 |